Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.60 |
| ▸ | DRD2 | P14416 | 8/20 | 0.60 |
| ▸ | DRD4 | P21917 | 4/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 6/20 | 0.53 |
| ▸ | HTR1A | P08908 | 5/20 | 0.53 |
| ▸ | HTR2C | P28335 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650872 | 0.94 | DRD3 (0.60) | DRD3DRD2DRD4ADRA1ALMNA | |
| SCHEMBL5651142 | 0.89 | DRD3 (0.66) | DRD3DRD2DRD4ADRA1ALMNA | |
| SCHEMBL5649853 | 0.87 | DRD3 (0.59) | DRD3DRD2ADRA1ALMNAMAPT | |
| SCHEMBL5653663 | 0.84 | KDM4E (0.57) | DRD3MAPTALDH1A1 | |
| SCHEMBL5649243 | 0.83 | DRD3 (0.57) | DRD3DRD2ADRA1ALMNAMAPT | |
| SCHEMBL5649253 | 0.83 | HTR2A (0.58) | DRD3DRD2ADRA1ALMNAMAPT | |
| SCHEMBL5652469 | 0.82 | DRD3 (0.58) | DRD3DRD2ADRA1ALMNAMAPT | |
| SCHEMBL5652458 | 0.82 | DRD3 (0.58) | DRD3DRD2ADRA1ALMNAMAPT | |
| SCHEMBL5651979 | 0.81 | DRD3 (0.57) | DRD3DRD2ADRA1ALMNAMAPT | |
| SCHEMBL5653653 | 0.78 | FGFR1 (0.58) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | DRD3 3697/4885DRD2 3803/4885DRD4 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.